Farmers & Merchants Investments Inc’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $84.4K | Hold |
170
| – | – | ﹤0.01% | 396 |
|
|
2026
Q1 | $75.9K | Hold |
170
| – | – | ﹤0.01% | 400 |
|
|
2025
Q4 | $77.1K | Buy |
170
+4
| +2% | +$1.72K | ﹤0.01% | 386 |
|
|
2025
Q3 | $65K | Hold |
166
| – | – | ﹤0.01% | 402 |
|
|
2025
Q2 | $73.9K | Buy |
166
+5
| +3% | +$2.3K | ﹤0.01% | 394 |
|
|
2025
Q1 | $78.1K | Hold |
161
| – | – | ﹤0.01% | 393 |
|
|
2024
Q4 | $64.8K | Sell |
161
-6
| -4% | -$2.78K | ﹤0.01% | 418 |
|
|
2024
Q3 | $77.7K | Hold |
167
| – | – | ﹤0.01% | 410 |
|
|
2024
Q2 | $78.3K | Sell |
167
-1
| -0.6% | -$434 | ﹤0.01% | 393 |
|
|
2024
Q1 | $70.2K | Buy |
168
+3
| +2% | +$1.27K | ﹤0.01% | 380 |
|
|
2023
Q4 | $67.1K | Sell |
165
-4
| -2% | -$1.48K | ﹤0.01% | 373 |
|
|
2023
Q3 | $58.8K | Buy |
169
+4
| +2% | +$1.4K | ﹤0.01% | 376 |
|
|
2023
Q2 | $58.1K | Sell |
165
-5
| -3% | -$1.69K | ﹤0.01% | 388 |
|
|
2023
Q1 | $53.6K | Buy |
170
+5
| +3% | +$1.5K | ﹤0.01% | 395 |
|
|
2022
Q4 | $47.6K | Hold |
165
| – | – | ﹤0.01% | 414 |
|
|
2022
Q3 | $48K | Buy |
165
+33
| +25% | +$9.49K | ﹤0.01% | 418 |
|
|
2022
Q2 | $37K | Hold |
132
| – | – | ﹤0.01% | 460 |
|
|
2022
Q1 | $34K | Sell |
132
-28
| -18% | -$6.64K | ﹤0.01% | 490 |
|
|
2021
Q4 | $35K | Hold |
160
| – | – | ﹤0.01% | 488 |
|
|
2021
Q3 | $29K | Buy |
160
+28
| +21% | +$5.47K | ﹤0.01% | 492 |
|
|
2021
Q2 | $27K | Hold |
132
| – | – | ﹤0.01% | 444 |
|
|
2021
Q1 | $28K | Hold |
132
| – | – | ﹤0.01% | 410 |
|
|
2020
Q4 | $31K | Hold |
132
| – | – | ﹤0.01% | 392 |
|
|
2020
Q3 | $36K | Hold |
132
| – | – | ﹤0.01% | 355 |
|
|
2020
Q2 | $38K | Buy |
132
+5
| +4% | +$1.36K | ﹤0.01% | 344 |
|
|
2020
Q1 | $30K | Buy |
127
+2
| +2% | +$459 | ﹤0.01% | 338 |
|
|
2019
Q4 | $27K | Buy |
125
+3
| +2% | +$607 | ﹤0.01% | 396 |
|
|
2019
Q3 | $21K | Hold |
122
| – | – | ﹤0.01% | 434 |
|
|
2019
Q2 | $22K | Buy |
122
+9
| +8% | +$1.57K | ﹤0.01% | 417 |
|
|
2019
Q1 | $21K | Buy |
113
+21
| +23% | +$3.88K | ﹤0.01% | 403 |
|
|
2018
Q4 | $15K | Hold |
92
| – | – | ﹤0.01% | 443 |
|
|
2018
Q3 | $18K | Buy |
92
+5
| +6% | +$890 | ﹤0.01% | 449 |
|
|
2018
Q2 | $15K | Hold |
87
| – | – | ﹤0.01% | 487 |
|
|
2018
Q1 | $14K | Buy |
87
+3
| +4% | +$490 | ﹤0.01% | 476 |
|
|
2017
Q4 | $13K | Buy |
84
+7
| +9% | +$1.04K | ﹤0.01% | 490 |
|
|
2017
Q3 | $12K | Buy |
77
+37
| +93% | +$5.57K | ﹤0.01% | 489 |
|
|
2017
Q2 | $5K | Buy |
40
+20
| +100% | +$2.41K | ﹤0.01% | 667 |
|
|
2017
Q1 | $2K | Hold |
20
| – | – | ﹤0.01% | 693 |
|
|
2016
Q4 | $1K | Hold |
20
| – | – | ﹤0.01% | 776 |
|
|
2016
Q3 | $2K | Hold |
20
| – | – | ﹤0.01% | 702 |
|
|
2016
Q2 | $2K | Hold |
20
| – | – | ﹤0.01% | 664 |
|
|
2016
Q1 | $2K | Hold |
20
| – | – | ﹤0.01% | 679 |
|
|
2015
Q4 | $3K | Hold |
20
| – | – | ﹤0.01% | 637 |
|
|
2015
Q3 | $2K | Buy |
+20
| New | +$2.57K | ﹤0.01% | 680 |
|
Other funds holding VRTX
Farmers & Merchants Investments Inc's VRTX Position: Q2 2026 in Review
Farmers & Merchants Investments Inc held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 170 shares worth $84.4K. The position accounts for ﹤0.01% of the portfolio, ranked #396.
Farmers & Merchants Investments Inc first reported a position in VRTX in Q3 2015 and has held it in 44 quarters since. 1,233 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Farmers & Merchants Investments Inc held 170 shares of Vertex Pharmaceuticals worth $84.4K as of Q2 2026.
- Farmers & Merchants Investments Inc left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
- Vertex Pharmaceuticals made up ﹤0.01% of Farmers & Merchants Investments Inc's portfolio in Q2 2026, its #396 holding.
- Farmers & Merchants Investments Inc first reported a position in Vertex Pharmaceuticals in Q3 2015 and has held it in 44 quarters since.
- 1,233 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Farmers & Merchants Investments Inc's 13F filing for Q2 2026, filed 20 Jul 2026.